File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patients

TitleEZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patients
Authors
Issue Date2010
PublisherOxford University Press. The Journal's web site is located at http://carcin.oxfordjournals.org/
Citation
Carcinogenesis, 2010, v. 31 n. 9, p. 1576-1583 How to Cite?
AbstractIt was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in ovarian carcinoma are unclear. In this study, EZH2 expression was examined by immunohistochemistry (IHC) in cohorts of normal and tumorous ovarian tissues. High expression of EZH2 was examined in none of the normal ovaries, in 3% of the cystadenomas, in 23% of the borderline tumors and in 50% of the ovarian carcinomas, respectively. In the ovarian carcinomas, high expression of EZH2 was positively correlated with an ascending histological grade and/or advanced stage of the disease (P < 0.05). Moreover, high expression of EZH2 in ovarian carcinoma was determined to be a strong and an independent predictor of short overall survival (P < 0.05). In ovarian carcinoma HO-8910 and UACC-326 cell lines, EZH2 knockdown by RNA interference led to a G 1 phase cell cycle arrest, reduced cell growth/proliferation and inhibited cell migration and/or invasion in vitro. In addition, EZH2 knockdown was found to reduce transforming growth factor-β1 (TGF-β1) expression and increase E-cadherin expression either in the transcript or in the protein levels. Furthermore, a significant positive correlation between overexpression of EZH2 and TGF-β1 in ovarian carcinoma tissues was observed (P < 0.001). These findings suggest a potential important role of EZH2 in the control of cell migration and/or invasion via the regulation of TGF-β1 expression, and the high expression of EZH2, as detected by IHC, is an independent molecular marker for shortened survival time of patients with ovarian carcinoma. © The Author 2010. Published by Oxford University Press. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/150831
ISSN
2014 Impact Factor: 5.334
2014 SCImago Journal Rankings: 2.152
ISI Accession Number ID
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
2010CB529401
Nature Science Foundation of China30772334
Funding Information:

Major State Basic Research Program of China (2006CB910104 and 2010CB529401); Nature Science Foundation of China (30772334).

References

 

DC FieldValueLanguage
dc.contributor.authorRao, ZYen_US
dc.contributor.authorCai, MYen_US
dc.contributor.authorYang, GFen_US
dc.contributor.authorHe, LRen_US
dc.contributor.authorMai, SJen_US
dc.contributor.authorHua, WFen_US
dc.contributor.authorLiao, YJen_US
dc.contributor.authorDeng, HXen_US
dc.contributor.authorChen, YCen_US
dc.contributor.authorGuan, XYen_US
dc.contributor.authorZeng, YXen_US
dc.contributor.authorKung, HFen_US
dc.contributor.authorXie, Den_US
dc.date.accessioned2012-06-26T06:11:40Z-
dc.date.available2012-06-26T06:11:40Z-
dc.date.issued2010en_US
dc.identifier.citationCarcinogenesis, 2010, v. 31 n. 9, p. 1576-1583en_US
dc.identifier.issn0143-3334en_US
dc.identifier.urihttp://hdl.handle.net/10722/150831-
dc.description.abstractIt was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in ovarian carcinoma are unclear. In this study, EZH2 expression was examined by immunohistochemistry (IHC) in cohorts of normal and tumorous ovarian tissues. High expression of EZH2 was examined in none of the normal ovaries, in 3% of the cystadenomas, in 23% of the borderline tumors and in 50% of the ovarian carcinomas, respectively. In the ovarian carcinomas, high expression of EZH2 was positively correlated with an ascending histological grade and/or advanced stage of the disease (P < 0.05). Moreover, high expression of EZH2 in ovarian carcinoma was determined to be a strong and an independent predictor of short overall survival (P < 0.05). In ovarian carcinoma HO-8910 and UACC-326 cell lines, EZH2 knockdown by RNA interference led to a G 1 phase cell cycle arrest, reduced cell growth/proliferation and inhibited cell migration and/or invasion in vitro. In addition, EZH2 knockdown was found to reduce transforming growth factor-β1 (TGF-β1) expression and increase E-cadherin expression either in the transcript or in the protein levels. Furthermore, a significant positive correlation between overexpression of EZH2 and TGF-β1 in ovarian carcinoma tissues was observed (P < 0.001). These findings suggest a potential important role of EZH2 in the control of cell migration and/or invasion via the regulation of TGF-β1 expression, and the high expression of EZH2, as detected by IHC, is an independent molecular marker for shortened survival time of patients with ovarian carcinoma. © The Author 2010. Published by Oxford University Press. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://carcin.oxfordjournals.org/en_US
dc.relation.ispartofCarcinogenesisen_US
dc.subject.meshAdenocarcinoma, Mucinous - Genetics - Metabolism - Pathologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCell Adhesionen_US
dc.subject.meshCell Cycleen_US
dc.subject.meshCell Movementen_US
dc.subject.meshCystadenocarcinoma, Serous - Genetics - Metabolism - Pathologyen_US
dc.subject.meshDna-Binding Proteins - Physiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene Expression Regulation, Neoplasticen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoenzyme Techniquesen_US
dc.subject.meshIn Situ Hybridization, Fluorescenceen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Invasivenessen_US
dc.subject.meshNeoplasm Metastasisen_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshOvarian Neoplasms - Genetics - Metabolism - Pathologyen_US
dc.subject.meshRna, Messenger - Geneticsen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshSurvival Rateen_US
dc.subject.meshTissue Array Analysisen_US
dc.subject.meshTranscription Factors - Physiologyen_US
dc.subject.meshTransforming Growth Factor Beta1 - Genetics - Metabolismen_US
dc.subject.meshTumor Cells, Cultureden_US
dc.subject.meshYoung Adulten_US
dc.titleEZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patientsen_US
dc.typeArticleen_US
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_US
dc.identifier.authorityGuan, XY=rp00454en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/carcin/bgq150en_US
dc.identifier.pmid20668008en_US
dc.identifier.scopuseid_2-s2.0-77956277833en_US
dc.identifier.hkuros183175-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956277833&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume31en_US
dc.identifier.issue9en_US
dc.identifier.spage1576en_US
dc.identifier.epage1583en_US
dc.identifier.isiWOS:000281530400010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridRao, ZY=36187169500en_US
dc.identifier.scopusauthoridCai, MY=39461062300en_US
dc.identifier.scopusauthoridYang, GF=16064823400en_US
dc.identifier.scopusauthoridHe, LR=35069492500en_US
dc.identifier.scopusauthoridMai, SJ=36780688900en_US
dc.identifier.scopusauthoridHua, WF=24401204900en_US
dc.identifier.scopusauthoridLiao, YJ=36114448500en_US
dc.identifier.scopusauthoridDeng, HX=24079601100en_US
dc.identifier.scopusauthoridChen, YC=24075600300en_US
dc.identifier.scopusauthoridGuan, XY=7201463221en_US
dc.identifier.scopusauthoridZeng, YX=7402981579en_US
dc.identifier.scopusauthoridKung, HF=7402514190en_US
dc.identifier.scopusauthoridXie, D=35070710200en_US
dc.identifier.citeulike7842375-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats